| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1872-034X.2007.00168.X |
| P698 | PubMed publication ID | 17877502 |
| P2093 | author name string | Hashem B El-Serag | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| epidemiology | Q133805 | ||
| P304 | page(s) | S88-94 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Epidemiology of hepatocellular carcinoma in USA | |
| P478 | volume | 37 Suppl 2 |
| Q33916361 | A multidisciplinary approach to the management of hepatocellular carcinoma |
| Q35997794 | Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease |
| Q41490805 | Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma |
| Q38161848 | After the cure: management of HCV after achievement of SVR. |
| Q34417009 | An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm |
| Q33391857 | An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. |
| Q30746254 | Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer |
| Q45195757 | Anticancer mechanisms of Strobilanthes crispa Blume hexane extract on liver and breast cancer cell lines |
| Q87406414 | Assessment of hepatitis C risk factors and infection prevalence in a jail population |
| Q34304174 | Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review |
| Q30485410 | Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies |
| Q89285709 | Barriers to Care in Chinese Immigrants with Hepatocellular Carcinoma: A Focus Group Study in New York City |
| Q34635064 | Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients |
| Q37461714 | Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker |
| Q39358916 | Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma |
| Q35740345 | Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma |
| Q39846767 | Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. |
| Q64955459 | Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. |
| Q37122782 | Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of eleven epidemiological studies |
| Q38560926 | Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma |
| Q42007162 | Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. |
| Q38033646 | Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis |
| Q33728121 | Contrast-enhanced computed tomography plus gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging for gross classification of hepatocellular carcinoma |
| Q40449077 | Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis. |
| Q38155511 | Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition |
| Q36376464 | Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways |
| Q35102566 | Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort |
| Q40020398 | Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre |
| Q53078137 | Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. |
| Q50573694 | Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. |
| Q34470706 | Disparities in Hepatocellular Carcinoma Survival among Californians of Asian Ancestry, 1988 to 2007 |
| Q37065327 | Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China |
| Q24187663 | Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma |
| Q24202061 | Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma |
| Q33937557 | Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study |
| Q34997752 | Effects of statins on the risk of hepatocellular carcinoma |
| Q36210228 | Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis |
| Q35593576 | Epidemiology of hepatitis C: related hepatocellular carcinoma in Cameroon |
| Q50672893 | Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective |
| Q34619389 | Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. |
| Q93111176 | Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma |
| Q33865082 | Fibrosis-dependent mechanisms of hepatocarcinogenesis |
| Q40071003 | From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world |
| Q28550036 | Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma |
| Q22241238 | Global cancer statistics |
| Q36644408 | Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies |
| Q38826455 | Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. |
| Q38615769 | Hepatitis B and C viruses and hepatocellular carcinoma |
| Q34852702 | Hepatitis B and Hepatocellular Carcinoma Screening Among Asian Americans: Survey of Safety Net Healthcare Providers |
| Q43648361 | Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection |
| Q37980432 | Hepatitis C virus induced insulin resistance impairs response to anti viral therapy |
| Q33600085 | Hepatitis C virus screening in patients with cancer receiving chemotherapy |
| Q45355364 | Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention |
| Q36006326 | Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease |
| Q92196392 | Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center |
| Q35790424 | Hepatocellular carcinoma in Asia: Prevention strategy and planning |
| Q37015123 | Hepatocellular carcinoma prevalence and mortality in a male state prison population |
| Q27489394 | Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis |
| Q26783881 | Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols |
| Q34633249 | Hepatocellular carcinoma: insight from animal models |
| Q37389382 | Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes |
| Q39813398 | Hospitalization for Complications of Cirrhosis: Does Volume Matter? |
| Q37094576 | INFLUENCE OF HEPATOCELLULAR CARCINOMA ETIOLOGY IN THE SURVIVAL AFTER RESECTION |
| Q37557988 | Identification of osteopontin as a novel marker for early hepatocellular carcinoma |
| Q90735307 | Imaging-Negative Hepatocellular Carcinoma Presents as an Intrabiliary Mass |
| Q44833504 | Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma |
| Q33812148 | Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization |
| Q35679343 | Insulin resistance and metabolic hepatocarcinogenesis with parent-of-origin effects in A×B mice |
| Q34197835 | Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma |
| Q28396741 | Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old |
| Q34150131 | Integrative genomic analysis identifies that SERPINA6-rs1998056 regulated by FOXA/ERα is associated with female hepatocellular carcinoma |
| Q39117807 | Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. |
| Q34466458 | Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? |
| Q27021321 | Laparoscopic-assisted ablation of hepatic tumors: a review |
| Q64984085 | Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. |
| Q33871866 | Liver Transplantation for Hepatocellular Carcinoma among African Americans in the United States |
| Q26997618 | Liver transplantation for hepatocellular carcinoma |
| Q37624357 | Local geographic variation in chronic liver disease and hepatocellular carcinoma: contributions of socioeconomic deprivation, alcohol retail outlets, and lifestyle |
| Q33828043 | Long non‑coding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma |
| Q37780114 | Long-term experience with liver transplantation for hepatocellular carcinoma |
| Q34580349 | Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase |
| Q26769611 | Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies? |
| Q34462989 | Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma |
| Q37031706 | Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma |
| Q39528390 | MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. |
| Q24635267 | Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma |
| Q30448048 | New paradigm for management of hepatocellular carcinoma by imaging |
| Q42636955 | Non-invasive quantitative imaging of hepatocellular carcinoma growth in mice by micro-CT using liver-targeted iodinated nano-emulsions |
| Q33381184 | Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. |
| Q42573914 | Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. |
| Q38081075 | Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes |
| Q90068282 | Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations |
| Q37727827 | Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. |
| Q39185282 | Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1. |
| Q35801608 | Pesticide exposure and hepatocellular carcinoma risk: A case-control study using a geographic information system (GIS) to link SEER-Medicare and California pesticide data |
| Q29248103 | Pesticide exposure and liver cancer: a review |
| Q42953743 | Population-based risk factors and resource utilization for HCC: US perspective |
| Q45348539 | Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force |
| Q51283174 | Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. |
| Q35178251 | Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization |
| Q34271258 | Prospective study of ultraviolet radiation exposure and risk of cancer in the United States |
| Q53085800 | Resource utilization and survival among Medicare patients with advanced liver disease. |
| Q35903837 | Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis |
| Q36858838 | Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. |
| Q31037974 | Retracted: Genetic Variations in Plasma Circulating DNA of HBV-Related Hepatocellular Carcinoma Patients Predict Recurrence after Liver Transplantation |
| Q33441277 | S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature |
| Q89966645 | S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness |
| Q85302763 | Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score |
| Q84742664 | Safety of liver resections in obese and overweight patients |
| Q41534186 | Serum fibronectin distinguishes the early stages of hepatocellular carcinoma |
| Q36680204 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review |
| Q24243619 | Surgical resection for hepatocellular carcinoma |
| Q24201773 | Surgical resection versus liver transplant for patients with hepatocellular carcinoma |
| Q34618740 | Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection |
| Q36197579 | The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia |
| Q36713138 | The gap in digestive organ cancers in Inner Mongolia, 2009-2012 |
| Q42988978 | The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States |
| Q37716630 | The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. |
| Q34758857 | Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. |
| Q34524584 | Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline |
| Q89766272 | Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey |
| Q28394316 | Trichloroethylene and cancer: systematic and quantitative review of epidemiologic evidence for identifying hazards |
| Q34143512 | Underutilization of therapy for hepatocellular carcinoma in the medicare population |
| Q53062216 | Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. |
| Q41505729 | Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy |
| Q37281965 | Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. |
| Q36987718 | mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. |
| Q36166685 | miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1) |
Search more.